You are here: Home » 0 » » Archives for 0st

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BurgerFi International, Inc. f/k/a Opes Acquisition Corp. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – BFI, OPES

NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BurgerFi International, Inc. f/k/a Opes Acquisition Corp. (NASDAQ: BFI, OPES) between December 17, 2020 and November 15, 2022, both dates inclusive (the "Class Period"), of the important June 5, 2023 lead plaintiff deadline.

SO WHAT: If you purchased BurgerFi securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the BurgerFi class action, go to https://rosenlegal.com/submit–form/?case_id=14148 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 5, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) BurgerFi had overstated the effectiveness of its acquisition and growth strategies; (2) BurgerFi had misrepresented to investors the purported benefits of the Anthony's Coal Fired Pizza & Wings acquisition and its post–business combination business and financial prospects; and (3) as a result, BurgerFi's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the BurgerFi class action, go to https://rosenlegal.com/submit–form/?case_id=14148 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8836475)

Nyxoah Nomme Christoph Eigenmann au Poste de Chief Commercial Officer

Nyxoah Nomme Christoph Eigenmann au Poste de Chief Commercial Officer

Mont–Saint–Guibert, Belgique "" 10 mai 2023, 22h05 CET / 16h05 ET "" Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) ( Nyxoah ou la Socit ) opre dans le secteur des technologies mdicales et se concentre sur le dveloppement et la commercialisation de solutions innovantes destines traiter le Syndrome d'Apnes Obstructives du Sommeil (SAOS). La Socit a annonc aujourd'hui la nomination de Christoph Eigenmann au poste de Chief Commercial Officer. Christoph supervisera les activits commerciales au niveau mondial et sera responsable des ventes et du marketing sur les marchs existants, ainsi que du dveloppement de nouveaux marchs.

Christoph apporte Nyxoah une grande exprience dans le domaine des technologies mdicales. Il a pass plus de 20 ans chez Johnson & Johnson (J&J), o il a supervis des organisations commerciales dans diverses zones gographiques en Europe et aux tats–Unis. Il possde une vaste exprience de la gestion des activits orthopdiques et neurologiques sur les marchs allemand, suisse et amricain, notamment en tant que Senior Vice President, Sales & Marketing pour la franchise Spine de J&J, qui reprsente prs d'un milliard de dollars aux tats–Unis, et il a dirig des fonctions rgionales dans la rgion EMEA et en Amrique du Nord. Christoph est titulaire d'un Master en gnie chimique et en biotechnologie de l'cole Polytechnique Fdrale de Lausanne, en Suisse.

“Nous sommes ravis que Christoph rejoigne Nyxoah au moment o nous entamons notre prochaine phase de croissance. Les annes d'exprience de Christoph dans la commercialisation de dispositifs mdicaux l'chelle mondiale seront inestimables alors que Nyxoah se prpare entrer sur le march amricain et tendre sa prsence commerciale l'chelle internationale”, a comment Olivier Taelman, CEO de Nyxoah.

“Je suis ravi de rejoindre Nyxoah en cette priode critique et passionnante. La stimulation du nerf hypoglosse est un march important et trs peu pntr, et l'approche novatrice de Nyxoah offre une solution trs diffrencie pour les patients, les cliniciens et les systmes de sant. Je suis impatient de mettre profit ma longue exprience de la commercialisation de dispositifs mdicaux aux tats–Unis pour faire en sorte que Genio devienne traitement de rfrence dans le traitement du SAOS”, a ajout Christoph.

propos de Nyxoah
Nyxoah opre dans le secteur des technologies mdicales. Elle se concentre sur le dveloppement et la commercialisation de solutions innovantes destines traiter le Syndrome d'Apnes Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le systme Genio , une thrapie de neurostimulation du nerf hypoglosse de nouvelle gnration centre sur le patient, sans sonde ni batterie implante et destine traiter le Syndrome d'Apnes Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associ un risque accru de mortalit et des comorbidits cardiovasculaires. Nyxoah est motiv par la vision selon laquelle les patients souffrant de SAOS devraient profiter de nuits reposantes et se sentir en mesure de vivre pleinement leur vie.

la suite de la finalisation probante de l'tude BLAST OSA, le systme Genio a reu le marquage europen CE en 2019. Nyxoah a ralis deux introductions en bourse avec succs : sur Euronext en septembre 2020 et au NASDAQ en juillet 2021. Suite aux rsultats positifs de l'tude BETTER SLEEP, Nyxoah a obtenu l'approbation marquage CE pour le traitement des patients atteints de Collapse Circonfrentiel Complet (CCC), actuellement contre–indiqu dans les thrapies concurrentes. De plus, la Socit mne actuellement l'tude pivot DREAM IDE en vue de l'approbation FDA et de la commercialisation aux tats–Unis.

Pour plus d'informations, visitez http://www.nyxoah.com/

Attention "" Marquage CE depuis 2019. Dispositif exprimental aux tats–Unis. Limit par la loi fdrale amricaine une utilisation exprimentale aux tats–Unis.

Contacts :
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Pice jointe


GLOBENEWSWIRE (Distribution ID 1000809330)